Black Diamond Therapeutics (BDTX) vs LENZ Therapeutics (LENZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Black Diamond Therapeutics (BDTX) has outperformed LENZ Therapeutics (LENZ) over the past year, losing 53.2% versus a loss of 92.3%. Over five years, BDTX leads with a -77.6% price change compared with -96.0% for LENZ. LENZ Therapeutics is the larger company by market cap ($113.7 million vs $104.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDTX | LENZ |
|---|---|---|
| Share price | $1.83 | $3.62 |
| Market cap | $104.86M | $113.74M |
| 1-day change | +1.67% | -4.49% |
| YTD return | -24.69% | -77.38% |
| 1-year return | -53.20% | -92.29% |
| 5-year return | -77.63% | -95.95% |
| EPS (TTM) | $-0.76 | $-3.94 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.94 | $49.25 |
| 52-week low | $1.60 | $3.46 |
| Distance from 52-week high | -62.96% | -92.65% |
| Average volume | 624.92K | 838.15K |
| Shares outstanding | 57.30M | 31.42M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BDTX has outperformed LENZ by 39.1 percentage points over the past year.
BDTX vs LENZ FAQ
Which is bigger, Black Diamond Therapeutics or LENZ Therapeutics?
LENZ Therapeutics (LENZ) is larger, with a market capitalization of $113.74M compared with $104.86M for Black Diamond Therapeutics (BDTX).
Which stock has performed better over the past year, BDTX or LENZ?
BDTX returned -53.20% over the past 12 months, compared with -92.29% for LENZ (price return, excluding dividends). Past performance does not predict future results.
Are Black Diamond Therapeutics and LENZ Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.